Progyny Inc (PGNY)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Progyny Inc (PGNY) Stock Forecast
Analysts expect Progyny (PGNY) to earn $2.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.38B. Of 12 analysts, 10 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 8.3% |
| Buy | 9 | 75.0% |
| Hold | 2 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 13.7% and revenue estimates rise 11.6%.
- Fiscal year ending Dec 31, 2026
- $2.11
- EPS consensus, revenue $1.38B
- Fiscal year ending Dec 31, 2027
- $2.40
- EPS consensus, revenue $1.54B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.11 | $2.10 to $2.13 | 8 | $1.38B | $1.37B to $1.38B | 10 |
| Dec 31, 2027 | $2.40 | $2.31 to $2.57 | 8 | $1.54B | $1.52B to $1.57B | 10 |
Quarterly Estimates
The EPS consensus rises from $0.35 for the quarter ending Dec 31, 2026 to $0.57 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.35 | $0.30 to $0.40 | 14 | $362.33M | $334.18M to $380.92M | 13 |
| Mar 31, 2027 | $0.57 | $0.55 to $0.61 | 5 | $366.82M | $360.77M to $375.30M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 7 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.4% from $2.08.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.11 | $2.08 | $2.08 | $2.08 | $2.08 | +1.4% |
| Fiscal year ending Dec 31, 2027 | $2.40 | $2.31 | $2.32 | $2.32 | $2.30 | +4.4% |
| Quarter ending Mar 31, 2027 | $0.57 | $0.55 | $0.55 | $0.55 | $0.55 | +4.8% |
Frequently Asked Questions About PGNY
What is the PGNY stock forecast?
Consensus analyst estimates put Progyny's EPS at $2.11 for the fiscal year ending Dec 31, 2026, on revenue of $1.38B. The consensus rating from 12 analysts is Buy.
How do analysts rate PGNY stock?
Of 12 analysts covering Progyny, 1 rates it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PGNY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.11, with estimates from $2.10 to $2.13 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.40, with estimates from $2.31 to $2.57 from 8 analysts.
What revenue do analysts expect from Progyny next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.38B, with estimates from $1.37B to $1.38B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.54B, with estimates from $1.52B to $1.57B.
How many analysts cover PGNY?
12 analysts rate Progyny stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PGNY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors